IDiyas

For the Inventor, By the Inventor

San Diego, CA, United States of America

Kyle T Tarantino

USPTO Granted Patents = 15 

 

Average Co-Inventor Count = 6.5

ph-index = 4

Forward Citations = 39(Granted Patents)


Location History:

  • San Diego, CA (US) (2014 - 2021)
  • Princeton, NJ (US) (2015 - 2023)

Company Filing History:

goldMedal15 out of 2,076 
 
Janssen Pharmaceutica Nv
 patents

Years Active: 2014-2023

Loading Chart...
Loading Chart...
15 patents (USPTO):
1. 11618744 - Benzoimidazoles as prolyl hydroxylase inhibitors (2023-04-04),
2. 10975062 - 4-aminoquinazolinyl compounds as prolyl hydroxylase inhibitors (2021-04-13),
3. 10851083 - Benzoimidazoles as prolyl hydroxylase inhibitors (2020-12-01),
4. 10246442 - 4-Aminoquinazolin compounds as prolyl hydroxylase inhibitors (2019-04-02),
5. 9682972 - 1,2,5-substituted benzimidazoles as flap modulators (2017-06-20),
6. 9682971 - 1,2,5-Substituted benzimidazoles as flap modulators (2017-06-20),
7. 9573940 - 4-aminoquinazolinyl-2-yl-1-pyrazole-4-carboxylic acid compounds as prolyl hydroxylase inhibitors (2017-02-21),
8. 9265770 - 1,2,5-substituted benzimidazoles as FLAP modulators (2016-02-23),
9. 9073923 - Benzoimidazoles as prolyl hydroxylase inhibitors (2015-07-07),
10. 9067917 - 1,2,5-substituted benzimidazoles as FLAP modulators (2015-06-30),
11. 9006251 - 4-aminoquinazolin-2-yl-1-pyrrazole-4-carboxylic acid compounds as prolyl hydroxylase inhibitors (2015-04-14),
12. 8937078 - Quinazolinones as prolyl hydroxylase inhibitors (2015-01-20),
13. 8865713 - Benzoimidazoles as prolyl hydroxylase inhibitors (2014-10-21),
14. 8796263 - 4-aminoquinazolin-2-yl-1-pyrrazole-4-carboxylic acid compounds as prolyl hydroxylase inhibitors (2014-08-05),
15. 8759345 - Benzoimidazoles as prolyl hydroxylase inhibitors (2014-06-24),

Title: The Innovative Contributions of Kyle T Tarantino

Introduction

Kyle T Tarantino is a prominent inventor based in San Diego, CA, known for his significant contributions to the field of pharmaceuticals. With a total of 15 patents to his name, Tarantino has made remarkable strides in developing compounds that target prolyl hydroxylase activity, which plays a crucial role in various disease states.

Latest Patents

Among his latest patents, Tarantino has developed benzoimidazoles as prolyl hydroxylase inhibitors. This invention focuses on benzoimidazole compounds that are useful in pharmaceutical compositions for treating disorders modulated by prolyl hydroxylase activity. Another notable patent involves 4-aminoquinazolinyl compounds, which are also designed as prolyl hydroxylase inhibitors. These compounds can be utilized in pharmaceutical methods to address conditions such as anemia, vascular disorders, metabolic disorders, and wound healing.

Career Highlights

Throughout his career, Kyle T Tarantino has worked with esteemed organizations, including Janssen Pharmaceutica NV. His work in these companies has allowed him to further his research and development in the pharmaceutical industry, contributing to innovative solutions for complex health issues.

Collaborations

Tarantino has collaborated with notable colleagues, including Michael H Rabinowitz and Mark D Rosen. These partnerships have fostered a collaborative environment that enhances the development of groundbreaking pharmaceutical inventions.

Conclusion

Kyle T Tarantino's innovative work in the field of pharmaceuticals, particularly in developing prolyl hydroxylase inhibitors, showcases his dedication to advancing medical science. His contributions continue to impact the treatment of various health conditions, solidifying his reputation as a leading inventor in the industry.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…